73 Results for "

HER3

" in MedChemExpress (MCE) Product Catalog:
Products (73)

73 Results for "HER3" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-100848
CAS No.: 1603845-32-4
Purity:  98.28%
Target:  

EGFR

Research Areas:  

Cancer

TX1-85-1 is an irreversible Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99275
CAS No.: 1262787-83-6
Synonyms: AMG-888; U3-1287

Target:  

EGFR Akt ERK PARP Survivin

Research Areas:  

Cancer

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99813
CAS No.: 2227102-46-5
Synonyms: HER3-DXd; U3-1402
Research Areas:  

Cancer

Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99507
CAS No.: 1969309-56-5
Synonyms: MCLA-128; PB4188; R040517

Target:  

EGFR

Research Areas:  

Cancer

Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99936
CAS No.: 1512559-37-3
Synonyms: LJM716

Target:  

EGFR

Research Areas:  

Cancer

Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P70322
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuReceptor tyrosine-protein kinase erbB-3/HER3, Fc; Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor HER3; ERBB3; HER3
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-164702
Synonyms: Izalontamab Brengitecan
BL-B01D1 is a bispecific ADC, which targets EGFR and HER3 through bispecific antibody Izalontamab (HY-P99676), and exhibits cytotoxicity against various cancer cells via inhibition of DNA replication and DNA synthesis by its ADC toxin ED04 (HY-153891). BL-B01D1 can be used in the study of cancer .
loading...
    loading...
Cat. No.: HY-P99676
CAS No.: 2559704-24-2
Synonyms: SI-B001; BL-B01D1 Antibody

Target:  

EGFR

Research Areas:  

Cancer

Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-P991097
Synonyms: PM-8002; BNT-327

Target:  

VEGFR PD-1/PD-L1

Research Areas:  

Cancer

Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .
loading...
    loading...
Cat. No.: HY-P99268
CAS No.: 1334296-12-6
Synonyms: SAR 256212; MM 121

Target:  

EGFR Apoptosis

Research Areas:  

Cancer

Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
loading...
    loading...
Cat. No.: HY-157813
CAS No.: 2964536-59-0
Purity:  98.10%
Research Areas:  

Cancer

2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan is a drug-linker conjugates for ADC, consiting of a cleavable linker and Exatecan (HY-13631). 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan can be linked to anti-Her3 antibody .
loading...
    loading...
Cat. No.: HY-141676
CAS No.: 1323151-45-6
Purity:  ≥96.0%
Target:  

EGFR

Research Areas:  

Others

HyT36 is a low molecular weight hydrophobic tag that promotes the degradation of fusion protein and pseudokinase Her3 [3].
loading...
    loading...
Cat. No.: HY-P99304
CAS No.: 1448327-63-6
Synonyms: Anti-Human ERBB3 Recombinant Antibody

Target:  

EGFR PI3K Akt p38 MAPK

Research Areas:  

Cancer

Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer .
loading...
    loading...
Cat. No.: HY-153796
CAS No.: 2103331-95-7
Purity:  99.57%
Target:  

PROTACs EGFR

Research Areas:  

Cancer

PROTAC Her3 Degrader-8 (Compound PP2) is a Her3 PROTAC degrader. PROTAC Her3 Degrader-8 promotes the ubiquitination and degradation of Her3. PROTAC Her3 Degrader-8 can be used in the study of lung adenocarcinoma and ovarian cancer .
loading...
    loading...
Cat. No.: HY-P99866
CAS No.: 1314238-96-4
Synonyms: MEHD-7945A; RG 7597

Target:  

EGFR Akt p38 MAPK Apoptosis

Research Areas:  

Cancer

Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream HER/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research [3].
loading...
    loading...
Cat. No.: HY-178836
CAS No.: 3077488-78-6
Research Areas:  

Cancer

Z56-L23 is a conjugate of RAS-targeting ADC cytotoxic payload-linker with anti-tumor activity. Z56-L23 can be conjugated with HER3 antibody, EGFR antibody or EGFRxHER3 bispecific antibody to form intact antibody-drug conjugates (ADCs). ADC molecules related to Z56-L23 effectively inhibit the proliferation of tumor cells and also significantly suppress tumor growth in xenograft mouse models. Z56-L23 can be used in the research of pancreatic cancer .
loading...
    loading...
Cat. No.: HY-177760
CAS No.: 1252037-41-4
Research Areas:  

Cancer

PrCP-7414 is a prolyl carboxypeptidase (PRCP) inhibitor. PrCP-7414 blocks PRCP-mediated activation of the IGF1R/HER3 signaling pathway and subsequent AKT activation. PrCP-7414 exhibits pro-apoptotic, anti-tumor and synergistic cytotoxic activities, and inhibits the proliferation and survival of triple-negative breast cancer cells. PrCP-7414 can be used for the research of breast cancer .
loading...
    loading...
Cat. No.: HY-B0426A
CAS No.: 140462-76-6
Synonyms: ALO4943A; KW4679
Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis [3].
loading...
    loading...
Cat. No.: HY-139616
CAS No.: 2484865-72-5
Purity:  99.51%
Target:  

Sec61 PD-1/PD-L1

Research Areas:  

Cancer

Sec61-IN-2 is a Sec61 inhibitor. Sec61-IN-2 shows a significant inhibitory effect on PD-1 related reporter gene cell models (PD1tsGluc) (IC50 = 42 nM), while it has almost no inhibitory activity in TNFα, Her3, and IL-2 pathway models. Sec61-IN-2 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-P991237
CAS No.: 2673271-78-6
Synonyms: HMBD-001

Target:  

EGFR

Research Areas:  

Cancer

Nezutatug (HMBD-001) is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. Nezutatug inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .
loading...
    loading...